Table 2 Subject characteristics and whole-body responses to SIT and MICT.

From: Sprint interval training decreases left-ventricular glucose uptake compared to moderate-intensity continuous training in subjects with type 2 diabetes or prediabetes

 

SIT

MICT

P

Pre

Post

Pre

Post

Group

Time

Group x Time

n

13

11

13

10

   

men/women, n

9/4

7/4

7/6

6/4

0.688*

  

T2DM/prediabetes, n

11/2

10/1

6/7

4/6

0.097*

  

At least one glucose lowering medication, n

9

 

4

 

0.115*

  

  Metformin

7

 

4

 

0.428*

  

  DPP-4 inhibitors (sitagliptin)

4

 

1

 

0.322*

  

  Sulfonylurea (glimepiride)

1

   

0.999*

  

Other medication, n

  Antihypertensives

5

 

6

 

0.999*

  

  Statins

4

 

3

 

0.999*

  

  Affective medication

  

3

 

0.220*

  

  Menopausal hormone therapy

1

 

2

 

0.999*

  

Age, yr

49 (47, 51)

 

49 (46, 51)

 

0.849†

  

Height, cm

173 (168, 179)

 

172 (167, 176)

 

0.614†

  

Weight, kg

88.9 (80.6, 97.2)

88.4 (80.1, 96.7)

91.5 (84.5, 98.6)

91.1 (84.0, 98.1)

0.620

0.083

0.952

BSA, m2

2.0 (1.9, 2.1)

2.0 (1.9, 2.1)

2.0 (2.0, 2.1)

2.0 (1.9, 2.1)

0.543

0.131

0.877

BMI

30.5 (28.5, 32.5)

30.3 (28.4, 32.3)

31.0 (29.4, 32.7)

30.8 (29.2, 32.5)

0.688

0.070

0.833

Fat, %

34.8 (31.4, 38.5)

33.8 (30.5, 37.5)

33.8 (30.8, 36.9)

32.9 (30.0, 36.0)

0.666

0.018

0.872

FFM, kg

57.0 (51.8, 62.2)

57.6 (52.4, 62.8)

59.6 (55.0, 64.2)

59.8 (55.2, 64.5)

0.492

0.109

0.541

VO2peak, ml·kg−1·min−1

25.7 (23.2, 28.2)

27.0 (24.6, 29.5)‡

27.0 (24.9, 29.2)

26.9 (24.6, 29.1)§

0.716

0.123

0.050

M-value, µmol·kg−1·min−1

20.6 (13.4, 27.7)

25.7 (18.4, 33.0)

15.7 (9.7, 21.6)

19.7 (13.6, 25.8)

0.237

0.001

0.657

HbA1c, %

5.7 (5.4, 6.0)

5.5 (5.2, 5.8)

5.8 (5.5, 6.0)

5.6 (5.3, 5.9)

0.704

0.002

0.844

HbA1c, mmol/mol

38.7 (35.5, 42.0)

36.9 (33.6, 40.2)

39.6 (36.9, 42.4)

37.6 (34.7, 40.5)

0.701

0.001

0.816

Fasting glucose, mmol/l

7.1 (6.5, 7.7)

7.0 (6.4, 7.6)

6.8 (6.3, 7.3)

7.0 (6.4, 7.5)

0.715

0.953

0.395

OGTT 2 h glucose, mmol/l

10.4 (8.6, 12.3)

9.1 (7.2, 11.1)

10.5 (8.9, 12.1)

10.3 (8.6, 12.0)

0.604

0.089

0.207

Fasting insulin, pmol/l

11.5 (7.8, 17.0)

11.6 (7.8, 17.2)

13.2 (9.5, 18.5)

13.5 (9.5, 19.0)

0.565

0.881

0.933

OGTT 2 h insulin, pmol/l

75.0 (50.3, 111.7)

71.1 (46.6, 108.4)

68.1 (48.1, 96.3)

62.9 (42.7, 92.5)

0.654

0.615

0.921

Glucose AUC in OGTT

1274 (1142, 1407)

1242 (1104, 1379)

1298 (1184, 1412)

1323 (1200, 1446)

0.527

0.905

0.413

Insulin AUC in OGTT

7162 (5264, 9746)

7109 (5181, 9756)

6871 (5273, 8954)

6748 (5106, 8920)

0.810

0.849

0.937

  1. The results are presented as means (95% CI) for age and height. For all other parameters the results are presented as model-based means (95% CI). Results have been reported previously by Sjöros et al.34. Group p-value indicates whether there is a level difference between the groups, time p-value displays the mean change between pre- and post-measurements and group x time p-value indicates whether the mean changes are different between the groups. SIT, sprint interval training; MICT, moderate-intensity continuous training; n, number of subjects; T2DM, type 2 diabetes mellitus; BSA, body surface area; FFM, fat free mass; AUC, area under curve; *Fisher’s exact test at baseline; †T-test; ‡SIT time effect, p = 0.013; §MICT time effect, p = 0.75. Significant differences are printed in boldface.
Back to article page